Prospective evaluation of fluorescence in situ hybridization for diagnosing urothelial carcinoma

  • Authors:
    • Tianhai Lin
    • Zhenhua Liu
    • Liangren Liu
    • Lu Yang
    • Ping Han
    • Peng Zhang
    • Qiang Wei
  • View Affiliations

  • Published online on: March 27, 2017     https://doi.org/10.3892/ol.2017.5926
  • Pages: 3928-3934
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Urothelial carcinoma (UC) is the most common type of cancer of the bladder and upper urinary tract, and is characterized by a high risk of recurrence and progression. Urine fluorescence in situ hybridization (FISH) is a technique that detects genetic aberrations in exfoliated cells in the urine, with specific probes for chromosomes 3, 7 and 17 and the p16 gene. To evaluate the diagnostic value of FISH in UC, 119 patients from November 2010 to June 2012 with suspected UC were recruited into a prospective, cross‑sectional study and were followed up for 12‑30 months. These patients received voided urine cytology and FISH tests, and underwent cystoscopy and/or ureteroscopy as a reference standard. The final diagnoses confirmed 73 patients with UC, located in the bladder, upper urinary tracts or the two. The sensitivity of FISH for detecting UC was superior to cytology, irrespective of tumor grade and stage: Overall, 80.8 vs. 32.9% (P<0.001); low grade, 75.8 vs. 12.1% (P<0.001); high grade, 85 vs. 50% (P<0.005); non‑muscle‑invasive, 81.1 vs. 28.3% (P<0.001) and muscle‑invasive, 80 vs. 45% (P<0.05), respectively. The specificities of the two tests were similar; overall, the specificity was 89.1% for cytology vs. 100% for FISH, and no significant difference was observed between the methods. Notably, FISH exhibited 100% sensitivity for cytologically non‑diagnostic UC, but 33.3% specificity. In conclusion, FISH is a reliable and non‑invasive diagnostic tool for bladder and upper urinary tract UC, particularly in patients with low‑grade or early stage tumors.
View Figures
View References

Related Articles

Journal Cover

May-2017
Volume 13 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Lin T, Liu Z, Liu L, Yang L, Han P, Zhang P and Wei Q: Prospective evaluation of fluorescence in situ hybridization for diagnosing urothelial carcinoma. Oncol Lett 13: 3928-3934, 2017.
APA
Lin, T., Liu, Z., Liu, L., Yang, L., Han, P., Zhang, P., & Wei, Q. (2017). Prospective evaluation of fluorescence in situ hybridization for diagnosing urothelial carcinoma. Oncology Letters, 13, 3928-3934. https://doi.org/10.3892/ol.2017.5926
MLA
Lin, T., Liu, Z., Liu, L., Yang, L., Han, P., Zhang, P., Wei, Q."Prospective evaluation of fluorescence in situ hybridization for diagnosing urothelial carcinoma". Oncology Letters 13.5 (2017): 3928-3934.
Chicago
Lin, T., Liu, Z., Liu, L., Yang, L., Han, P., Zhang, P., Wei, Q."Prospective evaluation of fluorescence in situ hybridization for diagnosing urothelial carcinoma". Oncology Letters 13, no. 5 (2017): 3928-3934. https://doi.org/10.3892/ol.2017.5926